Prediction of thromboembolic events and mortality by the CHADS2 and the CHA2DS2-VASc in COVID-19. Issue 6 (10th February 2021)

• Record Type: Journal Article
• Authors: Caro-Codón, Juan; Lip, Gregory Y H; Rey, Juan R; Iniesta, Angel M; Rosillo, Sandra O; Castrejon-Castrejon, Sergio; Rodriguez-Sotelo, Laura; Garcia-Veas, Jose M; Marco, Irene; Martinez, Luis A; Martin-Polo, Lorena; Merino, Carlos; Martinez-Cossiani, Marcel; Buño, Antonio; Gonzalez-Valle, Luis; Herrero, Alicia; Lopez-de-Sa, Esteban; Merino, Jose L
• Is Part Of: Europace. Volume 23:Issue 6(2021)
• Page Start: 937
• Page End: 947
• Publication Date: 2021-02-10
• Subjects: COVID-19 -- CHADS2 -- CHA2DS2-VASc -- Thromboembolism -- Mortality; Arrhythmia -- Treatment -- Periodicals; Cardiac pacing -- Periodicals; Catheter ablation -- Periodicals; Heart -- Physiology -- Periodicals; Electrophysiology -- Periodicals; 617.4120645
• DOI: 10.1093/europace/euab015
• Languages: English
• ISSNs: 1099-5129

Abstract

Abstract: Aims: Age, sex, and cardiovascular disease have been linked to thromboembolic complications and poorer outcomes in COVID-19. We hypothesize that CHADS2 and CHA2 DS2 -VASc scores may predict thromboembolic events and mortality in COVID-19. Methods and results: COVID-19 hospitalized patients with confirmed SARS-CoV-2 infection from 1 March to 20 April 2020 who completed at least 1-month follow-up or died were studied. CHADS2 and CHA2 DS2 -VASc scores were calculated. Given the worse prognosis of male patients in COVID-19, a modified CHA2 DS2 -VASc score (CHA2 DS2 -VASc-M) in which 1 point was given to male instead of female was also calculated. The associations of these scores with laboratory results, thromboembolic events, and death were analysed. A total of 3042 patients (mean age 62.3 ± 20.3 years, 54.9% male) were studied and 115 (3.8%) and 626 (20.6%) presented a definite thromboembolic event or died, respectively, during the study period [median follow 59 (50–66) days]. Higher score values were associated with more marked abnormalities of inflammatory and cardiac biomarkers. Mortality was significantly higher with increasing scores for CHADS2, CHA2 DS2 -VASc, and CHA2 DS2 -VASc-M ( P < 0.001 for trend). The CHA2 DS2 -VASc-M showed the best predictive value for mortality [area under the receiver operating characteristic curve (AUC) 0.820, P < 0.001 for comparisons]. All scores had poor predictive value for thromboembolic events (AUC 0.497, 0.490, and 0.541, respectively). Conclusion: The CHADS2, CHA2 DS2 -VASc, and CHA2 DS2 -VASc-M scores are significantly associated with all-cause mortality but not with thromboembolism in COVID-19 patients. They are simple scoring systems in everyday use that may facilitate initial 'quick' prognostic stratification in COVID-19.